P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Abstract Alzheimer’s disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still...
Saved in:
| Main Authors: | Juan Lantero‐Rodriguez, Anniina Snellman, Andrea L Benedet, Marta Milà‐Alomà, Elena Camporesi, Laia Montoliu‐Gaya, Nicholas J Ashton, Agathe Vrillon, Thomas K Karikari, Juan Domingo Gispert, Gemma Salvadó, Mahnaz Shekari, Christina E Toomey, Tammaryn L Lashley, Henrik Zetterberg, Marc Suárez‐Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2021-11-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202115098 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retinal tau phosphorylation in Alzheimer's disease: A mass spectrometry study
by: Jessica Santiago, et al.
Published: (2025-10-01) -
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01) -
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
by: Gemma Salvadó, et al.
Published: (2023-03-01) -
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
by: Menayit Tamrat Dresse, et al.
Published: (2025-07-01) -
18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2017-07-01)